FDA Drafting Proposal to Extend Disqualifications Agencywide

Clinical Trials Advisor
The FDA is drafting a proposed rule that would extend its authority so that clinical investigators disqualified for one type of trial, such as drugs, would be ineligible to conduct work on any other FDA-regulated investigational product, including biologics and devices.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $10.00